Clinical characteristics, outcomes and prognostic factors in KRAS mutant lung cancers: experience from a tertiary care cancer center in India
CONCLUSION: This is the largest dataset of KRAS mutant lung cancers from India. Brain metastases were higher in patients with G12C mutations and associated with poorer PFS and OS. G12C mutation and PS ≥ 2 were also associated with inferior PFS and OS. Experience with targeted therapy for KRAS mutations remains an area of future exploration due to the unavailability of these agents in India.PMID:38439805 | PMC:PMC10911678 | DOI:10.3332/ecancer.2024.1674 (Source: Ecancermedicalscience)
Source: Ecancermedicalscience - March 5, 2024 Category: Cancer & Oncology Authors: Vanita Noronha Laboni Sarkar Vijay Patil Nandini Menon Minit Shah Akash Pawar Oindrila Roy Chowdhury Omshree Shetty Anuradha Chougule Pratik Chandrani Rajiv Kaushal Trupti Pai Amit Janu Nivedita Chakrabarty Kumar Prabhash Source Type: research
Survival rate of cervical cancer: a five year review at a Major Teaching Hospital in Ghana, West Africa
Ecancermedicalscience. 2024 Feb 1;18:1663. doi: 10.3332/ecancer.2024.1663. eCollection 2024.ABSTRACTCervical cancer (CC) is one of the leading causes of cancer-related deaths among females in Ghana. Despite the magnitude of the public health challenge posed by CC in Ghana, survival data as well as reported incidence and mortality rates are primarily based on studies conducted in the capital city of the country. Even though age at diagnosis is known to affect the overall survival of CC patients, the role of this factor in the prognosis of CC patients in Ghana has not been sufficiently explored. The aim of this study was to ...
Source: Ecancermedicalscience - March 5, 2024 Category: Cancer & Oncology Authors: Joseph Daniels Kwesi Asante Judith Naa Odey Tackie Kofi Adesi Kyei Source Type: research
Quality assessment of a rural population-based cancer registry (PBCR) at Ratnagiri, Maharashtra, India for the years 2017-18
CONCLUSION: We have positive results regarding the data's validity and comparability, but there is scope for improvement concerning completeness. Continuous training of the registry personnel and monitoring of the registry is recommended.PMID:38439807 | PMC:PMC10911674 | DOI:10.3332/ecancer.2024.1672 (Source: Ecancermedicalscience)
Source: Ecancermedicalscience - March 5, 2024 Category: Cancer & Oncology Authors: Samyukta Shivshankar Monika Sarade Sandip Bhojane Suvarna Kolekar Suvarna Patil Atul Budukh Source Type: research
Determining the cost and cost-effectiveness of childhood cancer treatment in Haiti
Ecancermedicalscience. 2024 Feb 28;18:1675. doi: 10.3332/ecancer.2024.1675. eCollection 2024.ABSTRACTHaiti is a low-income country with one of the lowest human development index rankings in the world. Its childhood cancer services are provided by a single hospital with the only dedicated paediatric oncology department in the country. Our objective was to assess the cost and cost-effectiveness of all types of childhood cancer in Haiti to help prioritise investments and to support national cancer control planning. All costing data were collected from the year 2017 or 2018 hospital records. Costs were classified into 11 cost ...
Source: Ecancermedicalscience - March 5, 2024 Category: Cancer & Oncology Authors: Nancy S Bolous Peter Mercredi Miguel Bonilla Paola Friedrich Nickhill Bhakta Monika L Metzger Pascale Y Gassant Source Type: research
Paediatric oncology in the Eastern Mediterranean region (EMR): the current state and challenges
Ecancermedicalscience. 2024 Feb 28;18:1677. doi: 10.3332/ecancer.2024.1677. eCollection 2024.ABSTRACTThe WHO Eastern Mediterranean region (EMR) is characterised by highly economically diverse countries, with healthcare systems in various phases of development. Childhood cancer care provision also ranges from that provided in centres able to deliver sophisticated therapy resulting in outcomes comparable to those seen in highly developed nations, to countries with no provision for care of children with cancer. At 10·1 per 100,000 children at risk, the age standardised incidence-rate for cancer in children below 14 years of ...
Source: Ecancermedicalscience - March 5, 2024 Category: Cancer & Oncology Authors: Arsalan Kabir Siddiqui Asim Fakhruddin Belgaumi Source Type: research
